NYSE:PFE - Pfizer Stock Price, Price Target & More

$37.06 +0.26 (+0.71 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$37.06
Today's Range$36.7650 - $37.2650
52-Week Range$31.67 - $39.43
Volume25.44 million shs
Average Volume23.80 million shs
Market Capitalization$218.05 billion
P/E Ratio13.98
Dividend Yield3.71%
Beta0.9

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:PFE
CUSIP71708110
Phone212-733-2323

Debt

Debt-to-Equity Ratio0.47%
Current Ratio1.35%
Quick Ratio1.10%

Price-To-Earnings

Trailing P/E Ratio13.98
Forward P/E Ratio12.52
P/E Growth1.83

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.20
Cash Flow$3.7932 per share
Price / Cash9.77
Book Value$12.02 per share
Price / Book3.08

Profitability

EPS (Most Recent Fiscal Year)$2.65
Net Income$21.31 billion
Net Margins40.55%
Return on Equity25.21%
Return on Assets9.42%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000

How to Become a New Pot Stock Millionaire

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 18th. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share on Thursday, March 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer's previous quarterly dividend of $0.32. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its Board of Directors has initiated a share repurchase plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer (NYSE:PFE) posted its quarterly earnings data on Tuesday, January, 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.56 by $0.06. The biopharmaceutical company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.47 earnings per share. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY18 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.78. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $53.82 billion.

What price target have analysts set for PFE?

19 analysts have issued 12 month target prices for Pfizer's stock. Their predictions range from $31.00 to $43.00. On average, they expect Pfizer's share price to reach $39.2222 in the next year. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "Pfizer faces headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost cuts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. Additionally, Pfizer’s shares have outperformed the industry this year so far. Pfizer has a positive record of earnings surprises in recent quarters. Estimates have gone up slightly ahead of its Q1 earnings release." (4/12/2018)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)

Are investors shorting Pfizer?

Pfizer saw a decline in short interest in April. As of April 13th, there was short interest totalling 81,029,742 shares, a decline of 17.6% from the March 30th total of 98,318,686 shares. Based on an average daily volume of 20,554,014 shares, the short-interest ratio is presently 3.9 days. Approximately 1.4% of the company's shares are short sold.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Chairman & CEO (Age 64)
  • Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
  • Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
  • Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Has Pfizer been receiving favorable news coverage?

News stories about PFE stock have trended somewhat positive on Tuesday, according to Accern. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pfizer earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $37.06.

How big of a company is Pfizer?

Pfizer has a market capitalization of $218.05 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  961 (Vote Outperform)
Underperform Votes:  513 (Vote Underperform)
Total Votes:  1,474
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfizer (NYSE:PFE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Pfizer in the last 12 months. Their average twelve-month price target is $39.2222, suggesting that the stock has a possible upside of 5.83%. The high price target for PFE is $43.00 and the low price target for PFE is $31.00. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.372.422.532.53
Ratings Breakdown: 1 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $39.2222$39.3889$37.9333$38.3750
Price Target Upside: 5.83% upside9.75% upside3.02% upside6.13% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Jefferies GroupSet Price TargetHold$38.00LowView Rating Details
4/12/2018CitigroupReiterated RatingSellMediumView Rating Details
4/11/2018Berenberg BankReiterated RatingNeutral$37.00LowView Rating Details
4/5/2018BarclaysDowngradeOverweight -> Equal Weight$41.00 -> $38.00MediumView Rating Details
4/2/2018BMO Capital MarketsSet Price TargetBuy$43.00MediumView Rating Details
1/31/2018Credit Suisse GroupBoost Price TargetNeutral -> Neutral$37.00 -> $39.00MediumView Rating Details
1/31/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$35.00 -> $38.00MediumView Rating Details
1/31/2018UBSSet Price TargetBuy$42.00MediumView Rating Details
1/31/2018Morgan StanleyBoost Price TargetOverweight -> Buy$41.00 -> $43.00MediumView Rating Details
1/31/2018Societe GeneraleSet Price TargetNeutral$40.00MediumView Rating Details
1/30/2018Goldman SachsSet Price TargetNeutral$36.00HighView Rating Details
1/30/2018MorningstarSet Price TargetNeutral$38.00HighView Rating Details
1/30/2018Bank of AmericaSet Price TargetBuy$40.00MediumView Rating Details
1/30/2018JPMorgan ChaseReiterated RatingBuyLowView Rating Details
1/30/2018Sanford C. BernsteinSet Price TargetBuy$43.00LowView Rating Details
1/29/2018SunTrust BanksReiterated RatingHold -> Hold$33.00 -> $40.00LowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/6/2017Deutsche BankSet Price TargetBuy$38.00LowView Rating Details
8/14/2017CowenSet Price TargetBuy$43.00LowView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper JaffraySet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
5/4/2016Independent ResearchSet Price TargetNeutral$37.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Earnings Estimates

2018 EPS Consensus Estimate: $2.96
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.67$0.75$0.72
Q2 20182$0.70$0.75$0.73
Q3 20182$0.75$0.78$0.77
Q4 20182$0.69$0.82$0.76

Pfizer (NYSE PFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018$0.70N/AView Earnings Details
1/30/2018Q4 2017$0.5620$0.62$13.6746 billion$13.7030 billionViewListenView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.1749 billion$13.1680 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.0774 billion$12.8960 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.0890 billion$12.7790 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
11/2/2010Q3 2010$0.51$0.54ViewN/AView Earnings Details
8/3/2010Q2 2010$0.52$0.62ViewN/AView Earnings Details
5/4/2010Q1 2010$0.53$0.60ViewN/AView Earnings Details
2/3/2010Q4 2009$0.49$0.49ViewN/AView Earnings Details
10/20/2009Q3 2009$0.48$0.51ViewN/AView Earnings Details
7/22/2009Q2 2009$0.46$0.48ViewN/AView Earnings Details
4/28/2009Q1 2009$0.48$0.54ViewN/AView Earnings Details
1/26/2009Q4 2008$0.60$0.65ViewN/AView Earnings Details
10/21/2008Q3 2008$0.60$0.62ViewN/AView Earnings Details
7/23/2008Q2 2008$0.54$0.55ViewN/AView Earnings Details
4/17/2008Q1 2008$0.65$0.61ViewN/AView Earnings Details
1/23/2008Q4 2007$0.47$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pfizer (NYSE:PFE) Dividend Information

Pfizer pays an annual dividend of $1.36 per share, with a dividend yield of 3.67%. PFE's most recent quarterly dividend payment was Thursday, March 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 7.20% each year. Pfizer pays out 51.32% of its earnings out as a dividend.
Most Recent Dividend:3/1/2018
Annual Dividend:$1.36
Dividend Yield:3.67%
Dividend Growth:7.20% (3 Year Average)
Payout Ratio:51.32% (Trailing 12 Months of Earnings)
45.95% (Based on This Year's Estimates)
44.59% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/18/2017quarterly$0.343.68%2/1/20182/2/20183/1/2018
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 71.33%
Insider Trading History for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Douglas M LanklerInsiderSell50,000$36.89$1,844,500.00133,057View SEC Filing  
3/13/2018Rady A JohnsonEVPSell27,323$36.55$998,655.6570,332View SEC Filing  
3/9/2018Mikael DolstenInsiderSell69,699$36.59$2,550,286.41120,784View SEC Filing  
3/6/2018Charles H HillInsiderSell42,393$35.76$1,515,973.68View SEC Filing  
3/2/2018Mikael DolstenInsiderSell13,986$35.85$501,398.10120,884View SEC Filing  
2/27/2018Sally SusmanEVPSell33,368$37.03$1,235,617.04191,505View SEC Filing  
2/27/2018W Don CornwellDirectorSell1,758$36.79$64,676.821,000View SEC Filing  
2/26/2018Kirsten Lund-JurgensenInsiderSell9,510$37.19$353,676.9036,959View SEC Filing  
12/15/2017Alexander R MackenzieInsiderSell6,750$37.00$249,750.00103,458View SEC Filing  
12/15/2017Rady A JohnsonEVPSell8,000$37.07$296,560.0046,963View SEC Filing  
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00117,432View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50117,432View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00145,649View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00124,774View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00132,124View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00337,389View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00580,318View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.8074,506View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00151,474View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.0054,963View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.0057,329View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.7064,719View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00112,087View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50149,199View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00472,994View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00271,663View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.0071,659View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00564,994View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00200,399View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.5088,922View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.001,446,738View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00195,951View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00124,920View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48438,107View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35372,994View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.0099,647View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15171,756View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62344,571View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15173,637View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20356,451View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70118,383View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
Global Pneumococcal Vaccine Market Forecasts 2018-2023 - Key Players are Pfizer, Sanofi, GSK, Merck, AstraZeneca ...Global Pneumococcal Vaccine Market Forecasts 2018-2023 - Key Players are Pfizer, Sanofi, GSK, Merck, AstraZeneca ...
www.businesswire.com - April 24 at 3:34 PM
How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
finance.yahoo.com - April 24 at 3:34 PM
Biktarvy Could Be a Major Driver for Gilead Sciences in 2018Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
finance.yahoo.com - April 24 at 3:34 PM
Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA saysWegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says
finance.yahoo.com - April 24 at 3:34 PM
Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
finance.yahoo.com - April 24 at 10:29 AM
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and PfizerThe Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
finance.yahoo.com - April 24 at 10:29 AM
Pfizer (PFE) to Release Quarterly Earnings on TuesdayPfizer (PFE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 2:46 AM
Eli Lilly’s 1Q18 Estimates: Revenue Growth ExpectedEli Lilly’s 1Q18 Estimates: Revenue Growth Expected
finance.yahoo.com - April 23 at 3:34 PM
Don't Get Greedy With Novavax, Inc. StockDon't Get Greedy With Novavax, Inc. Stock
finance.yahoo.com - April 23 at 3:34 PM
BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba® (Meningococcal Group B Vaccine)BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba® (Meningococcal Group B Vaccine)
www.reuters.com - April 23 at 10:21 AM
BRIEF-Pfizer: EU Approves Mylotarg With Chemotherapy To Treat Acute Myeloid LeukemiaBRIEF-Pfizer: EU Approves Mylotarg With Chemotherapy To Treat Acute Myeloid Leukemia
www.reuters.com - April 23 at 10:21 AM
BRIEF-Pfizer Provides Update On Proposed Trastuzumab BiosimilarBRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar
www.reuters.com - April 23 at 10:21 AM
Pfizers Mylotarg OKd in Europe for certain type of AMLPfizer's Mylotarg OK'd in Europe for certain type of AML
seekingalpha.com - April 23 at 10:21 AM
Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)
finance.yahoo.com - April 22 at 10:09 AM
See Which Of The Latest 13F Filers Holds PfizerSee Which Of The Latest 13F Filers Holds Pfizer
www.nasdaq.com - April 21 at 10:18 AM
$13.03 Billion in Sales Expected for Pfizer (PFE) This Quarter$13.03 Billion in Sales Expected for Pfizer (PFE) This Quarter
www.americanbankingnews.com - April 21 at 1:56 AM
Asembia Expands Collaboration with Pfizer OncologyAsembia Expands Collaboration with Pfizer Oncology
www.prnewswire.com - April 20 at 10:55 AM
Pfizer (PFE) Given Consensus Recommendation of "Hold" by AnalystsPfizer (PFE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 20 at 3:28 AM
Pfizer (PFE) Expected to Post Earnings of $0.73 Per SharePfizer (PFE) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - April 19 at 11:14 PM
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLCFDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
finance.yahoo.com - April 19 at 3:37 PM
Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of ShareholdersPfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders
finance.yahoo.com - April 19 at 3:37 PM
Pfizer (PFE) Given a $43.00 Price Target by Cowen AnalystsPfizer (PFE) Given a $43.00 Price Target by Cowen Analysts
www.americanbankingnews.com - April 19 at 12:16 PM
Pfizer (PFE) to Post FY2020 Earnings of $3.18 Per Share, SunTrust Banks ForecastsPfizer (PFE) to Post FY2020 Earnings of $3.18 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - April 19 at 7:38 AM
How Analysts View Tetraphase Pharmaceuticals in April 2018How Analysts View Tetraphase Pharmaceuticals in April 2018
finance.yahoo.com - April 18 at 3:37 PM
BRIEF-IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending DisclosureBRIEF-IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure
www.reuters.com - April 18 at 10:38 AM
SunTrust Banks Weighs in on Pfizers Q1 2018 Earnings (PFE)SunTrust Banks Weighs in on Pfizer's Q1 2018 Earnings (PFE)
www.americanbankingnews.com - April 18 at 7:52 AM
Coke Versus Pepsi of Drugmakers? Wall Street Doesnt Buy ItCoke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It
finance.yahoo.com - April 17 at 3:43 PM
Pfizer Inc. Stock Has a Great Storyline Thats Not Panning OutPfizer Inc. Stock Has a Great Storyline That's Not Panning Out
finance.yahoo.com - April 17 at 10:44 AM
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales GuidanceJ&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
finance.yahoo.com - April 17 at 10:44 AM
Biovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR CongressBiovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress
www.prnewswire.com - April 17 at 3:42 AM
Pfizer Inc. Stock Has a Great Storyline That’s Not Panning OutPfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
investorplace.com - April 17 at 12:03 AM
Merck to move scientists and money toward promising cancer drugMerck to move scientists and money toward promising cancer drug
finance.yahoo.com - April 16 at 3:44 PM
Pfizer Doesnt Succeed In One Late-Stage Kidney Cancer Study, What Else Is Left On The Table?Pfizer Doesn't Succeed In One Late-Stage Kidney Cancer Study, What Else Is Left On The Table?
seekingalpha.com - April 16 at 10:27 AM
Pfizer (PFE) Short Interest Down 31.2% in MarchPfizer (PFE) Short Interest Down 31.2% in March
www.americanbankingnews.com - April 16 at 3:03 AM
Q1 2018 Earnings Forecast for Pfizer (PFE) Issued By Jefferies GroupQ1 2018 Earnings Forecast for Pfizer (PFE) Issued By Jefferies Group
www.americanbankingnews.com - April 16 at 1:17 AM
Brainstorm Health: Gene Editing Arms Race, Pfizer Duchenne Drug, Concentrated CaffeineBrainstorm Health: Gene Editing Arms Race, Pfizer Duchenne Drug, Concentrated Caffeine
fortune.com - April 14 at 3:20 PM
Berenberg Bank Analysts Give Pfizer (PFE) a $39.00 Price TargetBerenberg Bank Analysts Give Pfizer (PFE) a $39.00 Price Target
www.americanbankingnews.com - April 14 at 3:07 PM
Pfizer (PFE) Rating Increased to Outperform at BMO Capital MarketsPfizer (PFE) Rating Increased to Outperform at BMO Capital Markets
www.americanbankingnews.com - April 14 at 10:35 AM
Pfizer (PFE) Given a $35.00 Price Target at Jefferies GroupPfizer (PFE) Given a $35.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 14 at 10:05 AM
Pfizer takes big gene therapy step after acquisition in Chapel HillPfizer takes big gene therapy step after acquisition in Chapel Hill
finance.yahoo.com - April 13 at 3:39 PM
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy DrugPfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
finance.yahoo.com - April 13 at 3:39 PM
Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer BizMylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
finance.yahoo.com - April 13 at 3:39 PM
Tishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction LoanTishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction Loan
www.wsj.com - April 13 at 10:59 AM
Mylan Reportedly Interested Merck KGaA's Consumer Health UnitMylan Reportedly Interested Merck KGaA's Consumer Health Unit
finance.yahoo.com - April 13 at 10:59 AM
Pfizer (PFE) Given a $38.00 Price Target by Jefferies Group AnalystsPfizer (PFE) Given a $38.00 Price Target by Jefferies Group Analysts
www.americanbankingnews.com - April 13 at 9:39 AM
Dow Jones Component Pfizer Isn't Interested In Bristol — YetDow Jones Component Pfizer Isn't Interested In Bristol — Yet
finance.yahoo.com - April 12 at 3:40 PM
Pfizer (PFE) Rating Lowered to Hold at Zacks Investment ResearchPfizer (PFE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:33 PM
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular ...Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular ...
www.businesswire.com - April 12 at 11:33 AM
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular DystrophyPfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - April 12 at 11:33 AM
Pfizer’s Inlyta Expansion Thwarted by Failed Phase III StudyPfizer’s Inlyta Expansion Thwarted by Failed Phase III Study
finance.yahoo.com - April 12 at 11:33 AM

SEC Filings

Pfizer (NYSE:PFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pfizer (NYSE PFE) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.